查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1553530

iPS 細胞（誘導性多功能幹細胞）市場規模、佔有率和趨勢分析報告：按細胞來源類型、應用、最終用途、地區和細分市場預測，2024-2030 年

Induced Pluripotent Stem Cells Market Size, Share & Trends Analysis Report By Derived Cell Type (Hepatocytes, Fibroblasts), By Application (Drug Development), By End-use, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10個工作天內

價格

iPS細胞（誘導性多功能幹細胞）市場成長與趨勢：

根據Grand View Research, Inc.最新報告顯示，到2030年，全球iPS細胞（誘導性多功能幹細胞）市場規模將達到33.1億美元，2024年至2030年複合年成長率為10.21%，預計將持續成長。

iPS 細胞（誘導性多功能幹細胞）（iPSC）市場正在迅速擴大。 iPS細胞（誘導性多功能幹細胞）主要用於產生身體必需的所有細胞和組織，以對抗白血病、脊髓損傷、心血管疾病和糖尿病等疾病。

推動市場擴張的其他因素包括研究支出的增加、基因組學舉措的增加以及基因組工程在個人化治療中應用的快速成長。因此，iPSC 的採用加速，導致市場收益成長。例如，2020 年 10 月，Axxam SpA 和 FUJIFILM Cellular Dynamics, Inc. 宣佈建立策略夥伴關係，以推進藥物發現過程。透過使用能夠實現標靶評估、高通量篩檢(HTS) 和高內涵篩檢的尖端藥物發現技術，這項合作夥伴關係將為藥物發現研究人員和科學家提供基於 hiPSC 檢測的整合平台。

近年來，醫療保健發展和研究的趨勢顯著擴大，預計這一趨勢將對預測期內對 iPS 細胞（誘導性多功能幹細胞）的需求產生重大影響。擴大人類iPSC細胞株在精準醫療中的應用範圍以及日益重視幹細胞治療應用預計將成為推動iPS細胞（誘導性多功能幹細胞）市場擴張的重要因素。例如，根據兩家公司的聯合聲明，2021 年 3 月，Sana Biotechnology 獲得批准使用FUJIFILM Cellular Dynamics 的 iPSC 平台來創建商業性化細胞療法。細胞療法可以改善、修改或取代人類生物學，包括細胞、組織和器官。

COVID-19 大流行期間研究活動的活性化也促進了 iPSC 的研究。此外，科學家們不斷努力發現新的治療方法和治療方法來控制 SARS CoV-2 感染，這增加了對 iPSC 作為研究工具的需求。此外，iPS 細胞（誘導性多功能幹細胞）可用於研究人類病毒感染的病理學，因為它們可以產生生理上等效的類器官和器官模型。因此，它支撐著產業的發展。

此外，隨著專注於與 iPS 細胞相關的各種科學活動的行業的發展，政府和商業部門正在增加資金，公眾對幹細胞的認知也透過各種組織不斷提高。然而，細胞重編程成本高、倫理問題、流程耗時等挑戰在一定程度上阻礙了iPS細胞（誘導性多功能幹細胞）產業的發展。此外，低效率、潛在的腫瘤風險和糟糕的編程也是限制 iPSC 市場擴張的問題。

iPS細胞（誘導性多功能幹細胞）市場報告亮點

  • 以細胞來源類型來看，纖維母細胞部分佔比重最大，2023年為30.51%。醫療保健專業人員越來越偏好將成纖維母細胞作為皮膚問題的潛在治療方法，這正在推動該領域的發展。
  • 按應用來看，藥物研發領域佔比最大，2023年為49.03%。慢性病的流行、久坐的生活方式等增加了對個人化治療的需求，而製藥和生物技術公司對利用 iPS 細胞開發藥物的興趣日益濃厚，正在推動該行業的成長。
  • 按最終用途分類，製藥和生物技術公司佔最大佔有率，2023年為59.83%。該細分市場預計將主導市場，因為它使用 iPS 細胞（誘導性多功能幹細胞）製造和開發針對各種疾病的各種幹細胞產品和技術。
  • 2023年，北美將佔據36.11%的較大佔有率。這主要是由於創新系統和技術在藥物研究、毒性測試和疾病建模中的使用越來越多，其中幹細胞療法在該地區獲得接受是推動市場的主要原因。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第 3 章 iPS Cell（誘導性多功能幹細胞）市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場推動要素分析
    • 市場限制因素分析
  • iPS細胞（誘導性多功能幹細胞）市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析
    • COVID-19 影響分析

第4章 iPS細胞（誘導性多功能幹細胞）市場：依細胞來源類型估算與趨勢分析

  • 細分儀表板
  • 全球iPS細胞（誘導性多功能幹細胞）市場：依來源細胞類型的波動分析
  • 2018-2030年全球iPS細胞（誘導性多功能幹細胞）市場規模與趨勢分析（依細胞來源類型）
  • 肝細胞
  • 纖維母細胞
  • 角質形成細胞
  • 羊膜細胞
  • 其他

第5章 iPS細胞（誘導性多功能幹細胞）市場：依應用估算與趨勢分析

  • 細分儀表板
  • 全球iPS細胞（誘導性多功能幹細胞）市場：應用變化分析
  • 2018-2030年全球iPS細胞（誘導性多功能幹細胞）市場規模及趨勢分析（依應用）
  • 藥物開發
    • 2018-2030 年市場估計與預測
  • 組織工程與再生醫學
    • 2018-2030 年市場估計與預測
    • 神經病學
    • 整形外科
    • 腫瘤學
    • 心血管疾病和心肌梗塞
    • 糖尿病
    • 其他
  • 毒理學調查
    • 2018-2030 年市場估計與預測
  • 疾病模型
    • 2018-2030 年市場估計與預測

第6章 iPS 細胞（誘導性多功能幹細胞）市場：以最終用途進行估算與趨勢分析

  • 細分儀表板
  • 全球iPS細胞（誘導性多功能幹細胞）市場：以最終用途分類的波動分析
  • 2018-2030年全球iPS細胞（誘導性多功能幹細胞）市場規模與趨勢分析（依最終用途）
  • 學術研究所
  • 製藥和生物技術公司
  • 其他

第7章 iPS細胞（誘導性多功能幹細胞）市場：區域估計與趨勢分析

  • 2023 年及 2030 年區域市場佔有率分析
  • 區域市場儀表板
  • 2018-2030年市場規模、預測趨勢分析：
  • 北美洲
    • 2018-2030 年北美市場估計與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 2018-2030 年歐洲市場估計與預測
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 2018-2030 年亞太市場估計與預測
    • 日本
    • 中國
    • 印度
    • 韓國
    • 澳洲
    • 泰國
  • 拉丁美洲
    • 2018-2030 年拉丁美洲市場估計與預測
    • 巴西
    • 阿根廷
  • 中東/非洲
    • 2018-2030 年中東和非洲市場估計和預測
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章 競爭格局

  • 公司/競爭對手分類
  • 策略規劃
  • 2023 年企業市場分析
  • 公司簡介/上市公司
    • STEMCELL Technologies Inc.
    • Cellular Engineering Technologies Inc.
    • REPROCELL Inc.
    • Takara Bio, Inc.
    • Axol Bioscience Ltd.
    • Fate Therapeutics, Inc.
    • FUJIFILM Cellular Dynamics, Inc.
    • Cynata Therapeutics Limited
    • Evotec SE
    • Astellas Pharma Inc.
Product Code: GVR-4-68040-116-1

Induced Pluripotent Stem Cells Market Growth & Trends:

The global induced pluripotent stem cells market size is expected to reach USD 3.31 billion by 2030, registering to grow at a CAGR of 10.21% from 2024 to 2030 according to a new report by Grand View Research, Inc. The market for induced pluripotent stem cells (iPSC) is expanding quickly. The ability of induced pluripotent stem cells to generate any cell or tissue essential by the body to fight or combat illnesses such as leukemia, spinal cord injury, cardiovascular disease, and diabetes is the primary reason for their utilization.

Other factors driving market expansion include higher research funding, an increase in the number of genomics initiatives, and a surge in the application of genome engineering in personalized drugs. This has accelerated the adoption of iPSC, resulting in the market's profitable revenue growth. For instance, in October 2020, Axxam S.p.A. & FUJIFILM Cellular Dynamics, Inc. announced a strategic partnership to advance the drug discovery process. Through the use of the most cutting-edge drug discovery techniques to enable target evaluation, High-Throughput Screening (HTS), & High-Content Screening, the partnership will give drug development researchers along with scientists access to an integrative platform of hiPSC-based assays.

Investments in healthcare development and research have expanded significantly in recent years, and this trend is projected to have a significant impact on induced pluripotent stem cell demand over the forecast period. The expanding spectrum of human iPSC cell lines' applications in precision medicine and the growing emphasis on stem cell therapeutic applications are predicted to be important factors driving induced pluripotent stem cell market expansion. For instance, in March 2021, Sana Biotechnology, Inc. received authorization to use FUJIFILM Cellular Dynamics' iPSC platform for the creation of commercially available cell therapies, according to a joint statement from both companies. Cell therapies can improve, fix, or substitute human biology, including cells, tissues, and organs.

The rise in research activity during the COVID-19 pandemic also enhanced iPSC-based research. In addition, scientists' ongoing efforts to discover novel therapies and treatments to manage the SARS CoV-2 infection have increased the need for iPSCs as research tools. Furthermore, induced pluripotent stem cells can create organoids or organ models that are physiologically equivalent, thus they can be utilized to study the pathophysiology of viral infection in humans. Thus, propelling the industry growth.

Furthermore, the government and commercial sectors are expanding funding along with growing industry that focuses on various scientific activities linked to iPSCs, and people are becoming more aware of stem cells through various organizations. However, challenges such as the high cost of cell reprograming, ethical concerns, and lengthy processes are inhibiting the growth of the induced pluripotent stem cell industry to a certain extend Moreover, low efficiency, potential tumor risk, and insufficient programming are other concerns restricting the expansion of the iPSC market.

Induced Pluripotent Stem Cells Market Report Highlights:

  • By derived cell type, the fibroblasts segment accounted for the largest share of 30.51% in 2023. The growing preference among healthcare professionals for fibroblast as potential treatments for skin problems are propelling the segment growth.
  • By application, the drug developmentsegment accounted for the largest share of 49.03% in 2023. The prevalence of chronic diseases, sedentary lifestyle, and others increase the demand for personalized therapies, and the increasing interest of pharma & biotech companies to develop drugs with the help of iPS cells promotes the industry growth.
  • By end-user, the pharmaceutical & biotechnology companies segment accounted for the largest share of 59.83% in 2023. This segment is projected to dominate the market since they make and develop various stem cell products & technology for various diseases employing induced pluripotent stem cells.
  • North America held the larger share of 36.11% in 2023. This is mostly due to increased use of innovative systems and technologies in drug research, toxicity testing, and disease modeling, as well as the region's growing acceptance of stem cell therapies are the major reasons for driving the market.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
    • 1.2.1. Derived Cell Type Segment
    • 1.2.2. Application Segment
    • 1.2.3. End Use Segment
  • 1.3. Information analysis
  • 1.4. Market formulation & data visualization
  • 1.5. Data validation & publishing
  • 1.6. Information Procurement
    • 1.6.1. Primary Research
  • 1.7. Information or Data Analysis
  • 1.8. Market Formulation & Validation
  • 1.9. Market Model
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Induced Pluripotent Stem Cells Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Rising prevalence of chronic diseases
      • 3.2.1.2. Increasing research and development activities in stem cell therapies
      • 3.2.1.3. Growing adoption of personalized medicine
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High cost of treatment
  • 3.3. Induced Pluripotent Stem Cells Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Induced Pluripotent Stem Cells Market: Derived Cell Type Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global Induced Pluripotent Stem Cells Market Derived Cell Type Movement Analysis
  • 4.3. Global Induced Pluripotent Stem Cells Market Size & Trend Analysis, by Derived Cell Type, 2018 to 2030 (USD Million)
  • 4.4. Hepatocytes
    • 4.4.1. Hepatocytes market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.5. Fibroblasts
    • 4.5.1. Fibroblasts market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.6. Keratinocytes
    • 4.6.1. Keratinocytes market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.7. Amniotic Cells
    • 4.7.1. Amniotic cells market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.8. Others
    • 4.8.1. Others market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 5. Induced Pluripotent Stem Cells Market: Application Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global Induced Pluripotent Stem Cells Market Application Movement Analysis
  • 5.3. Global Induced Pluripotent Stem Cells Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
  • 5.4. Drug Development
    • 5.4.1. Drug development market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.5. Tissue Engineering & Regenerative Medicine
    • 5.5.1. Tissue engineering & regenerative medicine market estimates and forecasts 2018 - 2030 (USD Million)
    • 5.5.2. Neurology
      • 5.5.2.1. Neurology market estimates and forecasts 2018 - 2030 (USD Million)
    • 5.5.3. Orthopedics
      • 5.5.3.1. Orthopedics market estimates and forecasts 2018 - 2030 (USD Million)
    • 5.5.4. Oncology
      • 5.5.4.1. Oncology market estimates and forecasts 2018 - 2030 (USD Million)
    • 5.5.5. Cardiovascular & Myocardial Infarction
      • 5.5.5.1. Cardiovascular & myocardial infarction market estimates and forecasts 2018 - 2030 (USD Million)
    • 5.5.6. Diabetes
      • 5.5.6.1. Diabetes market estimates and forecasts 2018 - 2030 (USD Million)
    • 5.5.7. Others
      • 5.5.7.1. Others market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.6. Toxicology Research
    • 5.6.1. Toxicology research market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.7. Disease Modeling
    • 5.7.1. Disease modeling market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 6. Induced Pluripotent Stem Cells Market: End Use Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Global Induced Pluripotent Stem Cells Market End Use Movement Analysis
  • 6.3. Global Induced Pluripotent Stem Cells Market Size & Trend Analysis, by End use, 2018 to 2030 (USD Million)
  • 6.4. Academic & Research Institutes
    • 6.4.1. Academic & research institutes market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.5. Pharmaceutical & Biotechnology Companies
    • 6.5.1. Pharmaceutical & biotechnology companies market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.6. Others
    • 6.6.1. Others market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 7. Induced Pluripotent Stem Cells Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2023 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.4. North America
    • 7.4.1. North America market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.4.2. U.S.
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Competitive scenario
      • 7.4.2.3. Regulatory framework
      • 7.4.2.4. Target disease prevalence
      • 7.4.2.5. U.S. market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.4.3. Canada
      • 7.4.3.1. Key country dynamics
      • 7.4.3.2. Competitive scenario
      • 7.4.3.3. Regulatory framework
      • 7.4.3.4. Target disease prevalence
      • 7.4.3.5. Canada market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.4.4. Mexico
      • 7.4.4.1. Key country dynamics
      • 7.4.4.2. Competitive scenario
      • 7.4.4.3. Regulatory framework
      • 7.4.4.4. Target disease prevalence
      • 7.4.4.5. Mexico market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.5. Europe
    • 7.5.1. Europe market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.5.2. UK
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Competitive scenario
      • 7.5.2.3. Regulatory framework
      • 7.5.2.4. Target disease prevalence
      • 7.5.2.5. UK market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.5.3. Germany
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Competitive scenario
      • 7.5.3.3. Regulatory framework
      • 7.5.3.4. Target disease prevalence
      • 7.5.3.5. Germany market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.5.4. France
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Competitive scenario
      • 7.5.4.3. Regulatory framework
      • 7.5.4.4. Target disease prevalence
      • 7.5.4.5. France market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.5.5. Italy
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Competitive scenario
      • 7.5.5.3. Regulatory framework
      • 7.5.5.4. Target disease prevalence
      • 7.5.5.5. Italy market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.5.6. Spain
      • 7.5.6.1. Key country dynamics
      • 7.5.6.2. Competitive scenario
      • 7.5.6.3. Regulatory framework
      • 7.5.6.4. Target disease prevalence
      • 7.5.6.5. Spain market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.5.7. Denmark
      • 7.5.7.1. Key country dynamics
      • 7.5.7.2. Competitive scenario
      • 7.5.7.3. Regulatory framework
      • 7.5.7.4. Target disease prevalence
      • 7.5.7.5. Denmark market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.5.8. Sweden
      • 7.5.8.1. Key country dynamics
      • 7.5.8.2. Competitive scenario
      • 7.5.8.3. Regulatory framework
      • 7.5.8.4. Target disease prevalence
      • 7.5.8.5. Sweden market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.5.9. Norway
      • 7.5.9.1. Key country dynamics
      • 7.5.9.2. Competitive scenario
      • 7.5.9.3. Regulatory framework
      • 7.5.9.4. Target disease prevalence
      • 7.5.9.5. Norway market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Asia Pacific market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.6.2. Japan
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Competitive scenario
      • 7.6.2.3. Regulatory framework
      • 7.6.2.4. Target disease prevalence
      • 7.6.2.5. Japan market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.6.3. China
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Competitive scenario
      • 7.6.3.3. Regulatory framework
      • 7.6.3.4. Target disease prevalence
      • 7.6.3.5. China market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.6.4. India
      • 7.6.4.1. Key country dynamics
      • 7.6.4.2. Competitive scenario
      • 7.6.4.3. Regulatory framework
      • 7.6.4.4. Target disease prevalence
      • 7.6.4.5. India market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.6.5. South Korea
      • 7.6.5.1. Key country dynamics
      • 7.6.5.2. Competitive scenario
      • 7.6.5.3. Regulatory framework
      • 7.6.5.4. Target disease prevalence
      • 7.6.5.5. South Korea market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.6.6. Australia
      • 7.6.6.1. Key country dynamics
      • 7.6.6.2. Competitive scenario
      • 7.6.6.3. Regulatory framework
      • 7.6.6.4. Target disease prevalence
      • 7.6.6.5. Australia market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.6.7. Thailand
      • 7.6.7.1. Key country dynamics
      • 7.6.7.2. Competitive scenario
      • 7.6.7.3. Regulatory framework
      • 7.6.7.4. Target disease prevalence
      • 7.6.7.5. Thailand market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Latin America market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.7.2. Brazil
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Competitive scenario
      • 7.7.2.3. Regulatory framework
      • 7.7.2.4. Target disease prevalence
      • 7.7.2.5. Brazil market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.7.3. Argentina
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Competitive scenario
      • 7.7.3.3. Regulatory framework
      • 7.7.3.4. Target disease prevalence
      • 7.7.3.5. Argentina market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.8. MEA
    • 7.8.1. MEA market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.8.2. South Africa
      • 7.8.2.1. Key country dynamics
      • 7.8.2.2. Competitive scenario
      • 7.8.2.3. Regulatory framework
      • 7.8.2.4. Target disease prevalence
      • 7.8.2.5. South Africa market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key country dynamics
      • 7.8.3.2. Competitive scenario
      • 7.8.3.3. Regulatory framework
      • 7.8.3.4. Target disease prevalence
      • 7.8.3.5. Saudi Arabia market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.8.4. UAE
      • 7.8.4.1. Key country dynamics
      • 7.8.4.2. Competitive scenario
      • 7.8.4.3. Regulatory framework
      • 7.8.4.4. Target disease prevalence
      • 7.8.4.5. UAE market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.8.5. Kuwait
      • 7.8.5.1. Key country dynamics
      • 7.8.5.2. Competitive scenario
      • 7.8.5.3. Regulatory framework
      • 7.8.5.4. Target disease prevalence
      • 7.8.5.5. Kuwait market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company/Competition Categorization
  • 8.2. Strategy Mapping
  • 8.3. Company Market Position Analysis, 2023
  • 8.4. Company Profiles/Listing
    • 8.4.1. STEMCELL Technologies Inc.
      • 8.4.1.1. Company overview
      • 8.4.1.2. Financial performance
      • 8.4.1.3. Product benchmarking
      • 8.4.1.4. Strategic initiatives
    • 8.4.2. Cellular Engineering Technologies Inc.
      • 8.4.2.1. Company overview
      • 8.4.2.2. Financial performance
      • 8.4.2.3. Product benchmarking
      • 8.4.2.4. Strategic initiatives
    • 8.4.3. REPROCELL Inc.
      • 8.4.3.1. Company overview
      • 8.4.3.2. Financial performance
      • 8.4.3.3. Product benchmarking
      • 8.4.3.4. Strategic initiatives
    • 8.4.4. Takara Bio, Inc.
      • 8.4.4.1. Company overview
      • 8.4.4.2. Financial performance
      • 8.4.4.3. Product benchmarking
      • 8.4.4.4. Strategic initiatives
    • 8.4.5. Axol Bioscience Ltd.
      • 8.4.5.1. Company overview
      • 8.4.5.2. Financial performance
      • 8.4.5.3. Product benchmarking
      • 8.4.5.4. Strategic initiatives
    • 8.4.6. Fate Therapeutics, Inc.
      • 8.4.6.1. Company overview
      • 8.4.6.2. Financial performance
      • 8.4.6.3. Product benchmarking
      • 8.4.6.4. Strategic initiatives
    • 8.4.7. FUJIFILM Cellular Dynamics, Inc.
      • 8.4.7.1. Company overview
      • 8.4.7.2. Financial performance
      • 8.4.7.3. Product benchmarking
      • 8.4.7.4. Strategic initiatives
    • 8.4.8. Cynata Therapeutics Limited
      • 8.4.8.1. Company overview
      • 8.4.8.2. Financial performance
      • 8.4.8.3. Product benchmarking
      • 8.4.8.4. Strategic initiatives
    • 8.4.9. Evotec SE
      • 8.4.9.1. Company overview
      • 8.4.9.2. Financial performance
      • 8.4.9.3. Product benchmarking
      • 8.4.9.4. Strategic initiatives
    • 8.4.10. Astellas Pharma Inc.
      • 8.4.10.1. Company overview
      • 8.4.10.2. Financial performance
      • 8.4.10.3. Product benchmarking
      • 8.4.10.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 Global induced pluripotent stem cells market, by region, 2018 - 2030 (USD Million)
  • Table 3 Global induced pluripotent stem cells market, by derived cell type, 2018 - 2030 (USD Million)
  • Table 4 Global induced pluripotent stem cells market, by application, 2018 - 2030 (USD Million)
  • Table 5 Global induced pluripotent stem cells market, by end use, 2018 - 2030 (USD Million)
  • Table 6 North America induced pluripotent stem cells market, by country, 2018 - 2030 (USD Million)
  • Table 7 North America induced pluripotent stem cells market, by derived cell type, 2018 - 2030 (USD Million)
  • Table 8 North America induced pluripotent stem cells market, by application, 2018 - 2030 (USD Million)
  • Table 9 North America induced pluripotent stem cells market, by end use, 2018 - 2030 (USD Million)
  • Table 10 U.S. induced pluripotent stem cells market, by derived cell type, 2018 - 2030 (USD Million)
  • Table 11 U.S. induced pluripotent stem cells market, by application, 2018 - 2030 (USD Million)
  • Table 12 U.S. induced pluripotent stem cells market, by end use, 2018 - 2030 (USD Million)
  • Table 13 Canada induced pluripotent stem cells market, by derived cell type, 2018 - 2030 (USD Million)
  • Table 14 Canada induced pluripotent stem cells market, by application, 2018 - 2030 (USD Million)
  • Table 15 Canada induced pluripotent stem cells market, by end use, 2018 - 2030 (USD Million)
  • Table 16 Mexico induced pluripotent stem cells market, by derived cell type, 2018 - 2030 (USD Million)
  • Table 17 Mexico induced pluripotent stem cells market, by application, 2018 - 2030 (USD Million)
  • Table 18 Mexico induced pluripotent stem cells market, by end use, 2018 - 2030 (USD Million)
  • Table 19 Europe induced pluripotent stem cells market, by country, 2018 - 2030 (USD Million)
  • Table 20 Europe induced pluripotent stem cells market, by derived cell type, 2018 - 2030 (USD Million)
  • Table 21 Europe induced pluripotent stem cells market, by application, 2018 - 2030 (USD Million)
  • Table 22 Europe induced pluripotent stem cells market, by end use, 2018 - 2030 (USD Million)
  • Table 23 Germany induced pluripotent stem cells market, by derived cell type, 2018 - 2030 (USD Million)
  • Table 24 Germany induced pluripotent stem cells market, by application, 2018 - 2030 (USD Million)
  • Table 25 Germany induced pluripotent stem cells market, by end use, 2018 - 2030 (USD Million)
  • Table 26 UK induced pluripotent stem cells market, by derived cell type, 2018 - 2030 (USD Million)
  • Table 27 UK induced pluripotent stem cells market, by application, 2018 - 2030 (USD Million)
  • Table 28 UK induced pluripotent stem cells market, by end use, 2018 - 2030 (USD Million)
  • Table 29 France induced pluripotent stem cells market, by derived cell type, 2018 - 2030 (USD Million)
  • Table 30 France induced pluripotent stem cells market, by application, 2018 - 2030 (USD Million)
  • Table 31 France induced pluripotent stem cells market, by end use, 2018 - 2030 (USD Million)
  • Table 32 Italy induced pluripotent stem cells market, by derived cell type, 2018 - 2030 (USD Million)
  • Table 33 Italy induced pluripotent stem cells market, by application, 2018 - 2030 (USD Million)
  • Table 34 Italy induced pluripotent stem cells market, by end use, 2018 - 2030 (USD Million)
  • Table 35 Spain induced pluripotent stem cells market, by derived cell type, 2018 - 2030 (USD Million)
  • Table 36 Spain induced pluripotent stem cells market, by application, 2018 - 2030 (USD Million)
  • Table 37 Spain induced pluripotent stem cells market, by end use, 2018 - 2030 (USD Million)
  • Table 38 Denmark induced pluripotent stem cells market, by derived cell type, 2018 - 2030 (USD Million)
  • Table 39 Denmark induced pluripotent stem cells market, by application, 2018 - 2030 (USD Million)
  • Table 40 Denmark induced pluripotent stem cells market, by end use, 2018 - 2030 (USD Million)
  • Table 41 Sweden induced pluripotent stem cells market, by derived cell type, 2018 - 2030 (USD Million)
  • Table 42 Sweden induced pluripotent stem cells market, by application, 2018 - 2030 (USD Million)
  • Table 43 Sweden induced pluripotent stem cells market, by end use, 2018 - 2030 (USD Million)
  • Table 44 Norway induced pluripotent stem cells market, by derived cell type, 2018 - 2030 (USD Million)
  • Table 45 Norway induced pluripotent stem cells market, by application, 2018 - 2030 (USD Million)
  • Table 46 Norway induced pluripotent stem cells market, by end use, 2018 - 2030 (USD Million)
  • Table 47 Asia Pacific induced pluripotent stem cells market, by country, 2018 - 2030 (USD Million)
  • Table 48 Asia Pacific induced pluripotent stem cells market, by derived cell type, 2018 - 2030 (USD Million)
  • Table 49 Asia Pacific induced pluripotent stem cells market, by application, 2018 - 2030 (USD Million)
  • Table 50 Asia Pacific induced pluripotent stem cells market, by end use, 2018 - 2030 (USD Million)
  • Table 51 China induced pluripotent stem cells market, by application, 2018 - 2030 (USD Million)
  • Table 52 China induced pluripotent stem cells market, by derived cell type, 2018 - 2030 (USD Million)
  • Table 53 China induced pluripotent stem cells market, by end use, 2018 - 2030 (USD Million)
  • Table 54 Japan induced pluripotent stem cells market, by derived cell type, 2018 - 2030 (USD Million)
  • Table 55 Japan induced pluripotent stem cells market, by application, 2018 - 2030 (USD Million)
  • Table 56 Japan induced pluripotent stem cells market, by end use, 2018 - 2030 (USD Million)
  • Table 57 India induced pluripotent stem cells market, by derived cell type, 2018 - 2030 (USD Million)
  • Table 58 India induced pluripotent stem cells market, by application, 2018 - 2030 (USD Million)
  • Table 59 India induced pluripotent stem cells market, by end use, 2018 - 2030 (USD Million)
  • Table 60 South Korea induced pluripotent stem cells market, by derived cell type, 2018 - 2030 (USD Million)
  • Table 61 South Korea induced pluripotent stem cells market, by application, 2018 - 2030 (USD Million)
  • Table 62 South Korea induced pluripotent stem cells market, by end use, 2018 - 2030 (USD Million)
  • Table 63 Australia induced pluripotent stem cells market, by derived cell type, 2018 - 2030 (USD Million)
  • Table 64 Australia induced pluripotent stem cells market, by application, 2018 - 2030 (USD Million)
  • Table 65 Australia induced pluripotent stem cells market, by end use, 2018 - 2030 (USD Million)
  • Table 66 Thailand induced pluripotent stem cells market, by derived cell type, 2018 - 2030 (USD Million)
  • Table 67 Thailand induced pluripotent stem cells market, by application, 2018 - 2030 (USD Million)
  • Table 68 Thailand induced pluripotent stem cells market, by end use, 2018 - 2030 (USD Million)
  • Table 69 Latin America induced pluripotent stem cells market, by country, 2018 - 2030 (USD Million)
  • Table 70 Latin America induced pluripotent stem cells market, by derived cell type, 2018 - 2030 (USD Million)
  • Table 71 Latin America induced pluripotent stem cells market, by application, 2018 - 2030 (USD Million)
  • Table 72 Latin America induced pluripotent stem cells market, by end use, 2018 - 2030 (USD Million)
  • Table 73 Brazil induced pluripotent stem cells market, by derived cell type, 2018 - 2030 (USD Million)
  • Table 74 Brazil induced pluripotent stem cells market, by application, 2018 - 2030 (USD Million)
  • Table 75 Brazil induced pluripotent stem cells market, by end use, 2018 - 2030 (USD Million)
  • Table 76 Argentina induced pluripotent stem cells market, by derived cell type, 2018 - 2030 (USD Million)
  • Table 77 Argentina induced pluripotent stem cells market, by application, 2018 - 2030 (USD Million)
  • Table 78 Argentina induced pluripotent stem cells market, by end use, 2018 - 2030 (USD Million)
  • Table 79 MEA induced pluripotent stem cells market, by country, 2018 - 2030 (USD Million)
  • Table 80 MEA induced pluripotent stem cells market, by derived cell type, 2018 - 2030 (USD Million)
  • Table 81 MEA induced pluripotent stem cells market, by application, 2018 - 2030 (USD Million)
  • Table 82 MEA induced pluripotent stem cells market, by end use, 2018 - 2030 (USD Million)
  • Table 83 South Africa induced pluripotent stem cells market, by derived cell type, 2018 - 2030 (USD Million)
  • Table 84 South Africa induced pluripotent stem cells market, by application, 2018 - 2030 (USD Million)
  • Table 85 South Africa induced pluripotent stem cells market, by end use, 2018 - 2030 (USD Million)
  • Table 86 Saudi Arabia induced pluripotent stem cells market, by derived cell type, 2018 - 2030 (USD Million)
  • Table 87 Saudi Arabia induced pluripotent stem cells market, by application, 2018 - 2030 (USD Million)
  • Table 88 Saudi Arabia induced pluripotent stem cells market, by end use, 2018 - 2030 (USD Million)
  • Table 89 UAE induced pluripotent stem cells market, by derived cell type, 2018 - 2030 (USD Million)
  • Table 90 UAE induced pluripotent stem cells market, by application, 2018 - 2030 (USD Million)
  • Table 91 UAE induced pluripotent stem cells market, by end use, 2018 - 2030 (USD Million)
  • Table 92 Kuwait induced pluripotent stem cells market, by derived cell type, 2018 - 2030 (USD Million)
  • Table 93 Kuwait induced pluripotent stem cells market, by application, 2018 - 2030 (USD Million)
  • Table 94 Kuwait induced pluripotent stem cells market, by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Market formulation & validation
  • Fig. 4 Induced pluripotent stem cells market: Market outlook
  • Fig. 5 Induced pluripotent stem cells market: Segment outlook
  • Fig. 6 Induced pluripotent stem cells market: Competitive landscape outlook
  • Fig. 7 Parent market outlook
  • Fig. 8 Induced pluripotent stem cells market driver impact
  • Fig. 9 Induced pluripotent stem cells market restraint impact
  • Fig. 10 Induced pluripotent stem cells market: Type outlook and key takeaways
  • Fig. 11 Induced pluripotent stem cells market: Type movement analysis
  • Fig. 12 Hepatocytes market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 13 Fibroblasts market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 14 Keratinocytes market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 15 Amniotic cells market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 16 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 17 Induced pluripotent stem cells market: Application outlook and key takeaways
  • Fig. 18 Induced pluripotent stem cells market: Application movement analysis
  • Fig. 19 Drug development market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 Tissue engineering & regenerative medicine market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 Neurology market estimates and forecasts,2018 - 2030 (USD Million)
  • Fig. 22 Orthopedics market estimates and forecasts,2018 - 2030 (USD Million)
  • Fig. 23 Oncology market estimates and forecasts,2018 - 2030 (USD Million)
  • Fig. 24 Cardiovascular and myocardial infarction market estimates and forecasts,2018 - 2030 (USD Million)
  • Fig. 25 Diabetes market estimates and forecasts,2018 - 2030 (USD Million)
  • Fig. 26 Others market estimates and forecasts,2018 - 2030 (USD Million)
  • Fig. 27 Toxicology research market estimates and forecasts,2018 - 2030 (USD Million)
  • Fig. 28 Disease modeling market estimates and forecasts,2018 - 2030 (USD Million)
  • Fig. 29 Induced pluripotent stem cells market: End use outlook and key takeaways
  • Fig. 30 Induced pluripotent stem cells market: End use movement analysis
  • Fig. 31 Academic & research institutes market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Pharmaceutical & biotechnology companies market estimates and forecasts,2018 - 2030 (USD Million)
  • Fig. 33 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Global induced pluripotent stem cells market: Regional outlook and key takeaways
  • Fig. 35 Global induced pluripotent stem cells market: Regional movement analysis
  • Fig. 36 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Key country dynamics
  • Fig. 38 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Key country dynamics
  • Fig. 40 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Key country dynamics
  • Fig. 42 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Key country dynamics
  • Fig. 45 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Key country dynamics
  • Fig. 47 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Key country dynamics
  • Fig. 49 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Key country dynamics
  • Fig. 51 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Key country dynamics
  • Fig. 53 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Key country dynamics
  • Fig. 55 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 Key country dynamics
  • Fig. 57 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Key country dynamics
  • Fig. 59 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Key country dynamics
  • Fig. 62 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 63 Key country dynamics
  • Fig. 64 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 65 Key country dynamics
  • Fig. 66 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 67 Key country dynamics
  • Fig. 68 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 69 Key country dynamics
  • Fig. 70 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 71 Key country dynamics
  • Fig. 72 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 73 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 74 Key country dynamics
  • Fig. 75 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 76 Key country dynamics
  • Fig. 77 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 78 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 79 Key country dynamics
  • Fig. 80 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 81 Key country dynamics
  • Fig. 82 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 83 Key country dynamics
  • Fig. 84 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 85 Key country dynamics
  • Fig. 86 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)